Since 2001, targeted therapy using tyrosine kinase inhibitor (TKI) drugs (Imatinib and its variants) has been highly successful in eradicating the CD34(–) BCR-ABL(+) cells and has improved outcomes in CML. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.